Dollarama Inc. (DOL.TO)

This is heading into the seasonal buy cycle and the stock is building a nice technical base. He expects to see this around $58 on the seasonal rally. It has a Central America partner that will add to its growth. He thinks investors are looking at this as a defensive holding. Yield 0.3%. (Analysts’ price target is $62.86)

He really likes it as a company. He has not owned it in a while but it was a mistake. It was always out of his price range. He has a hard time with the valuation.

This has been an amazing stock. Demographics are very attractive allowing for good gains. However, as prices have moved up, their sales are being effected. He would watch future sales and margins for signals of stagnation. A great company with great management. He would continue to hold for now.

It corrected in January, but is trading above its 200-day moving average. That said, its 50-day moving average is moving down, which is a concern. Its valuation is also high. Tariffs may hurt them, which could increase prices and limit revenues. He's neutral about this stock.

He has been too bearish on this company in the past. Now, however, with the yield below 1% and greater competition in the space, he would prefer to take profits or look elsewhere.

It is a great, great company. A truly Canadian success story. He is wary of the valuation at close to 30 times earnings recently. Grocers are half that. It has pretty good visibility. They think they can get to 1700 stores before the market is saturated. The next leg of growth is Latin America. They grow dividends and buy back stock with very little competition. He would buy on a pull back.

The chart makes this a rock star, although it has paused recently. This business is a pure momentum growth stock that always trades at a rich multiple – it is always expensive. He tends to stay away from these stocks as the risk is too great of buying at the wrong time. It only pays less than 0.5% yield.

It's always been expensive, but he bought after a bad report three years ago. It's trading at 25x next year's earnings, so still pricey, but they are great operators. Strong same-store sales growth and they are opening more stores. There's room to grow. Recently, the stock pulled back and has been flat for the year, so take advantage of this lull. Their Q1 earnings report blamed the bad weather. Sales may make up for that loss in Q2.

It's looked expensive for a number of years and now looks cheap--but it just did a stock split. If they do an earnings miss, they will dip 8-10%. That's an opportunity. DOL carries a little higher risk than normal. It's expensive, though well-run. Quebec is the last bastion of growth for them. The U.S. has too much competition for them. In 5-10 years this will run into growth problems.

It just split 3-1, which creates liquidity. He likes this stock. It's dealing with all-time highs, but with a now-limited upside.

He thinks this is massively overvalued, given it sells “junk” items. It has a 30 times multiple. He would rather buy McDonald’s with a 20 times earnings multiple.

He's be happy to be long this and sees a little bit of upside left here. It split today and expects it to see $70. The next quarter should be good, because the bad weather this quarter will lead to pent-up demand.

Only 27 Canadian companies match his screen. This one met the 30% ROE hurdle. He still sees a good runway for growth and likes the growth prospects in South America, where they have a store count of 101 locations now in a minority position with an option to become the majority holder. Yield 0.3%. (Analysts’ price target is $55.94)

(A Top Pick July 10/17 Up 29%) They are extremely well run and have a great runway for future growth. They do not do anything haphazard and they price competitively.

Had a good day today, but earnings lately a bit soft. Started taking a position when it was basing in April/May, and held a full position by early June. Market liked that they’re going to focus much more on Latin area expansion. Likely to become a majority shareholder in Dollar City. Increased both their eps guidance for 2019 and 2020, as well as their share buyback allowance. Drug capx marries well with the technical bottom you can see. (Analysts’ price target is $167.50.)